ABSI

NASDAQ 已收盘

Absci

8.16 USD
▼-0.02-0.24%
盘后 8.09 -0.86%
2026-11-19
市值
$1.30B
市盈率
—
EPS
-0.79
股息率
—
52 周区间
2.24 – 12.55
成交量
5.08M
Beta
2.19
目标价
15.09
52W 低 2.2452W 高 12.55
价格走势

公司简介

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket...